Clinical Trial Update: Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study investigating LDE225 in combination with gemcitabine and nab-paclitaxel in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LDE225 (sonidegib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED